vWDI is inherited in an autosomal dominant manner with incomplete penetrance, in the Kromfohrländer breed

Julia H. Segert, Jana-Marie Seidel, Walter J. Wurzer and Anja M. Geretschlaeger

Abstract

Background: Von Willebrand disorder type I (vWDI) is known as an inherited bleeding disorder in different dog breeds following an autosomal recessive inheritance. The Kromfohrländer is a rare dog breed with an increased incidence of unclear bleeding episodes and prolonged coagulation time during/after surgery or injuries, indicating a defect in one or more critical proteins of the coagulation cascade.

Objective: The objective of this study was to determine whether the c.7437G > A mutation in the VWF gene previously shown to cause von Willebrand disorder type I in Doberman Pinscher is also linked to this disease in the Kromfohrländer breed and to serum concentrations of vWF. Furthermore, establish a possible link between bleeding phenotype, vWF serum concentrations and VWF mutation status.

Results: Eighty-seven Kromfohrländer were genotyped for the G > A von Willebrand type I mutation. For detection of the associated mutation we used an endpoint genotyping method. We identified the G > A von Willebrand type I mutation in 80.5% of our study population. 65.5% were heterozygous (WT/MUT) and 15.0% were homozygous for the mutation (MUT/MUT). 21% of the overall study population exhibited bleeding symptoms. 45.5% of all homozygous dogs (MUT/MUT) showed bleeding symptoms. In contrast, wild-type homozygotes exhibited no bleeding symptoms, whereas 23.2% of the heterozygotes did. VWF serum concentrations varied from 28 to 137% in wild-type dogs while in heterozygous and homozygous dogs the concentration ranged from 3 to 77% and 1 to 23%, respectively (p < 0.05)

Conclusion: Based on our data, we found the G > A mutation in the VWF gene in the Kromfohrländer breed and the subsequent vWDI as the underlying cause for the bleeding episodes and delayed coagulation in heterozygous and homozygous dogs. Since both, heterozygotes and homozygotes show reduced vWF serum concentrations and exhibit to a certain percentage the VWD syndrome phenotype, we postulate that, in contrast to most other vWDI affected breeds, inheritance follows an autosomal dominant mode with incomplete penetrance.

Keywords: Von Willebrand disease, Von Willebrand factor, Genetic disorder, Genetic testing, Kromfohrländer

Plain english summary

A variety of bleeding diseases are known in dogs including von Willebrand disease type I. This genetic disorder affects the von Willebrand factor in plasma which is important for blood clotting. A genetic mutation known from the Doberman Pinscher was also found in other dog breeds including the Kromfohrländer. Inheritance of the disorder is described in most breeds as autosomal recessive trait resulting in mild bleeding symptoms.

The Kromfohrländer is an especially rare breed based on two founders which was established in the years after World War II in Germany. Reports on excessive bleeding during surgeries, birth or neutering/spaying are well known but without any clear association to a von Willebrand bleeding disorder. For this reason we were interested in finding a link between the von Willebrand disease type I mutation and a reduced plasma von
humans vWD is one of the most common inherited results in von Willebrand disease (vWD). In dogs and in the blood plasma. A deficiency or defective vWF aggregation. These multimers vary in size and circulate plasma glycoprotein required for platelet adhesion and the von Willebrand factor (vWF) is a large multimeric protein. Type I is inherited as an autosomal recessive trait. In the Kromfohrländer breed, symptoms of bleeding were not only observed in homozygous but also in heterozygous dogs. Based on this finding, heredity of von Willebrand Disease type I in the Kromfohrländer follows an autosomal dominant inheritance with incomplete penetrance resulting in severe bleeding symptoms in the Kromfohrländer breed. To avoid further distribution of the mutation within the population it would be of importance to perform genetic testing with a long term breeding program for reducing the number of heterozygous and homozygous dogs without an additional reduction of the genetic diversity.

**Background**

The von Willebrand factor (VWF) is a large multimeric plasma glycoprotein required for platelet adhesion and aggregation. These multimers vary in size and circulate in the blood plasma. A deficiency or defective VWF results in von Willebrand disease (vWD). In dogs and in humans vWD is one of the most common inherited bleeding disorders [1, 2]. vWD can be classified in 3 different types based on the clinical severity and quantity of von Willebrand factor. Type I is the most common type of vWD in dogs and accounts for more than 95% of all cases, meaning that nearly all canine cases can be classified as a type I disorder [3]. This type is characterized by low plasma VWF concentrations responsible for mild to moderate bleeding symptoms. Patients with a type II disorder have variably reduced VWF in plasma with an abnormal multimeric structure resulting in moderate to severe bleeding. This type of VWD is rare in dogs and to date VWD type II has been only described for German Shorthaired Pointers and German Wirehaired Pointers [4, 5]. A novel VWF variant associated with VWD type II in German Shorthaired and German Wirehaired Pointers was reported in 2017 by Vos-Loohuis et al. [6]. This second variant possibly acts in concert with the long thought causative VWDII mutation to cause the bleeding disorder in the Pointer breeds. Type III is rare in dogs as well and only found in Scottish Terriers [7, 8], Shetland Sheepdogs [7, 9], Kooikerhondje [10, 11] and Chesapeake Bay Retriever [12]. This is the most severe form of vWD with no detectable amount of VWF in plasma [13].

The causal mutation for VWD type II in the Doberman Pinscher and is caused by a G > A (OMIA ref.: [14]) transversion in the last nucleotide of exon 43 coding for von Willebrand factor [3, 15]. This base substitution activates a cryptic splice site just few nucleotides upstream of the normal splice site. The resulting frame shift leads to the formation of a truncated protein of 119 amino acids [15]. The same mutation was also found in various other breeds [16]. In most of these breeds inheritance of VWD type II was described as an autosomal recessive trait unlike the human disorder, which is inherited in an autosomal dominant manner with incomplete penetrance.

The Kromfohrländer (Fig. 1a and b) was established in the years after World War II in Germany based on two founders dogs, most likely a Griffon Vendéen and a Fox Terrier but the exact breeds remain unclear. From these progenies the Kromfohrländer was bred and 10 years later in 1955 was first recognized by Fédération Cynologique Internationale (FCI). The Kromfohrländer is an exceptionally rare breed with a small number of registered dogs in different stud books. In 2018, 7 dogs of this breed were registered in Austria and 229 in Germany. Based on a small number of founders and the early recognition by the FCI resulting in closed stud-books, the inbreeding level of the Kromfohrländer is very high. The small population size for more than 50 years hasn’t spared the breed from disorders like epilepsy, hyperkeratosis, hereditary cataracts, cystinuria and autoimmune disorders like immune mediated hemolytic anemia or polyarthritis. Some of these disorders like hereditary footpad hyperkeratosis [17] or hyperuricosuria [18] can be genetically tested.

To avoid a further increase in disorders and improve the health situation as well as genetic diversity within the Kromfohrländer, a cross breeding program with Dansk-Svensk Gårdshund (Danish–Swedish Farmdog) was initiated from the breeding club ProKromfohrländer e. V. in Germany. Health and genetic monitoring of Kromfohrländer which is part of this breeding program showed a high number of dogs being heterozygous and homozygous for the VWD mutation. Reports on excessive bleeding during surgeries, birth or neutering/spaying in the past are well known but without any clear association to a VWDI bleeding disorder.

The purpose of this study was to investigate if the G > A mutation in the VWF gene known and firstly reported from the Doberman Pinscher also leads to typical VWDI symptoms in Kromfohrländer dogs due to a reduced VWF serum concentration in both, heterozygotes and homozygotes. Moreover, we wanted to test the hypothesis that VWDI in the Kromfohrländer is unlike most
other breeds in that it is inherited as an autosomal dominant trait with an incomplete penetrance comparable to the mode of inheritance in human vWDI and establish a causal link between reports of excessive bleeding and the disorder.

**Material & methods**

**Study Population** – Purebred Kromfohrländer as well as F1, F2 and F3 siblings from outcross matings with Dansk-Svensk Gårdshund were included in this study. Dogs of different ages were recruited through ProKromfohrländer e.V. Germany or dog owners who voluntarily supported the study. In cases for which there was no genetic testing result for vWDI, dog owners were asked to submit buccal swabs for performing genetic vWDI testing. Sample material was collected from all untested and available Kromfohrländer however with a special interest in those dogs that already showed typical signs of bleeding episodes.

**Medical history questionnaire**

All study participants received a survey questionnaire to quantify the tendency of bleeding for each dog. Questionnaires were mailed to breeders or dog owners by a member of ProKromfohrländer e. V. Germany. The survey covered questions about haemorrhage, surgeries, spontaneous bleeding tendency in daily life as well during heat. Clinical data were submitted for all study dogs with an exception of 3 participants.

**Sample handling and preparation**

Samples for DNA testing were non-invasively collected using buccal swabs. Sampling was performed by dog owners according to a detailed instruction. After taking mucosa samples from the muzzle, swabs were dried and sent back for determination of the genetic vWDI status. DNA from mucosa cells was purified with the automated DNA extraction system EZ1 advanced XL (Qiagen, Hilden, Germany) using the Investigator kit (Qiagen, Hilden, Germany) according to the manufacturers manual. DNA was quantified by using the Quantus™ Fluorimeter (Promega, Mannheim, Germany) and the QuantiFluor dsDNA System (Promega, Mannheim, Germany). DNA samples were diluted to a final concentration of 2 ng μl⁻¹ with nuclease free water for subsequent genotyping PCR.

**Plasma von Willebrand factor and vWDI genotyping**

Results of % blood vWF level were forwarded to our laboratory on dog owner’s initiative or ProKromfohrländer e.V. Germany. The gene variant of vWDI c.7437G > A was determined by KASP genotyping according to the manufacturers manual (LGC Genomics Ltd., UK). The assay was designed against the vWDI mutation within a 50 base pair upstream and downstream region of the G > A mutation. The WT allele was labelled with FAM and the vWDI associated allele with HEX. Amplification reactions contained 5 μl of extracted gDNA (2 ng μl⁻¹) in a total reaction volume of 10 μl, complemented with 2x KASP master mix (Standard Rox, LGC Genomics Ltd., UK). Cycling conditions were carried out according to the manufacturer’s specifications using a Roche 480 Light Cycler (Roche, Basel, Switzerland). Samples of study dogs were used in replicates for a total of two genotyping PCRs, according to the standards and guidelines for clinical canine genetic testing laboratories [19]. For evaluation, endpoint genotyping was used to distinguish three possible cluster groups referring to the genotypes: WT/WT = c.7437G; WT/MUT = c.7437G + c.7437A; MUT/MUT = c.7437A. For each run negative controls (NT) without template consisting of 5 μl KASP master mix supplemented with nuclease free water were used.

**Results**

**Study population**

87 Kromfohrländer composed of 62% females and 38% males including purebred Kromfohrländer, as well as F1,
F2 and F3 so called project dogs from outcross matings with Dansk-Svensk Gårdshund (Danish–Swedish Farmdog) as part of the outcross program in the ProKromfohrländer e. V. Germany were included in this study. Of all study dogs 73.5% were purebred Kromfohrländer, 2.4% were F1 offspring from Kromfohrländer x Dansk-Svensk Gårdshund crosses, 18.3% were F2 offspring from F1 mating with a purebred Kromfohrländer and 5.8% were F3 offspring from F2 mating with a purebred Kromfohrländer (Table 1). The age span of all dogs was between 0.7 and 15 years with a median age of 3 years and an average age of 5 years. The biggest proportion, 44.8%, was between 1 to 4 years followed by 20.7 and 18.4% between 4 to 8 years and 8 to 12 years. About 9.2% were below one year and 6.9% older than 12 years.

vWDI genotyping results
For genetic testing, study dogs were categorized in three different groups, wild-type (WT/WT), heterozygous (WT/MUT) and homozygous (MUT/MUT) for the vWDI mutation. Based on the genotyping data for the G > A transversion in the last nucleotide of exon 43 coding for von Willebrand factor (Fig. 2), 19.5% were wild-type (WT/WT), 65.5% were heterozygous (WT/MUT) and 15.0% were homozygous (MUT/MUT) (Fig. 3). The frequency of the mutated allele within the study population is 48%. Within the group of purebred Kromfohrländer, 14.9% were wild-type (WT/WT), 47.1% were heterozygous (WT/MUT) and 11.5% were homozygous (MUT/MUT) for the vWDI mutation. In the F1 offspring from outcross mating only wild-type or heterozygotes were detected, while in the F2 and F3 offspring all three genotypes (wild-type, heterozygous and homozygous) were present (Table 1).

Bleeding tendencies
Information on bleeding tendencies was based on owner questionnaires which were provided for all study dogs with an exception of 3 dogs. Questions were primarily related to preceding surgeries or prolonged bleeding times for example during second dentition, heat, birth, implantations for chemical castration, injuries, or prolonged bleeding time after vaccination, as well as bruising and spontaneous epistaxis.

Of all tested Kromfohrländer, 21% showed bleeding symptoms compared to 76% of dogs without clinical signs up to the time the data were collected. For 3% no information about bleeding symptoms was available. In the case of two study dogs a definite classification was difficult. Nevertheless, based on the following description of symptoms we decided to assign both to the symptomatic group of dogs. One dog tested heterozygous (WT/MUT) for the vWDI mutation showed prolonged bleeding times, poor wound healing and encrusted pinna-rims. The second dog, tested homozygous (MUT/MUT), had a severely bleeding wound on his leg. It was not fully clear whether the severity of the injury caused the excessive bleeding or if there was indeed a direct association with von Willebrand’s symptoms because during a previous c-section this bitch was asymptomatic.

The most commonly reported symptoms in affected dogs were an excessive and prolonged bleeding during heat, prolonged bleeding times and hematomas after injuries, and massive hematomas and bleeding after castration in males. In the course of surgery, severe difficulties to stop bleeding were noted. After surgery, clinically affected dogs developed large area hematomas due to haemorrhages. In addition excessive bleeding during second dentition and gingival bleeding were observed. Hematomas also occurred after taking blood or implantations for chemical castration. Spontaneous epistaxis was also reported from several study dogs.

Based on the information obtained from owner questionnaires the distribution of symptomatic and asymptomatic dogs within the different genotype groups was determined (Fig. 4). Dogs without available clinical data were excluded from this calculation. Within the wild-type group (WT/WT) of dogs tested for the vWDI mutation, none showed symptoms related to von Willebrand disease. Within the group of heterozygous vWDI dogs (WT/MUT) 76.8% were asymptomatic while 23.2% showed symptoms of von Willebrand syndrome. Among the dogs homozygous for the disease causing mutation (MUT/MUT) 45.5% showed symptoms, while 54.5% were asymptomatic up to the time of data collection. Kromfohrländer homozygous for the vWDI mutation showed prolonged bleeding times, poor wound healing and encrusted pinna-rims. The second study dog tested heterozygous (WT/MUT) for the vWDI mutation followed by 18.3% F2 offspring. Genotype distribution shows a clear shift to heterozygotes (WT/MUT) within all 4 breed states.

Table 1 Distribution of study dogs based on breed status and genotype

| Breed Status | WT/WT | WT/MUT | MUT/MUT | Total |
|--------------|-------|--------|---------|-------|
| Purebred     | 14.9% | 47.1%  | 11.5%   | 73.5% |
| F1 offspring | 1.2%  | 1.2%   | 0.0%    | 2.4%  |
| F2 offspring | 2.3%  | 13.7%  | 2.3%    | 18.3% |
| F3 offspring | 1.2%  | 3.4%   | 1.2%    | 5.8%  |

Purebred Kromfohrländer as well as different offspring generations from a cross breeding program with Dansk-Svensk Gårdshund (Danish–Swedish Farmdog) were included in this study. The distribution based on the breed status and the corresponding genotype (wild-type (WT/WT), heterozygous (WT/MUT), homozygous (MUT/MUT)) is shown in this table. With 73.5% most study dogs where purebred Kromfohrländer followed by 18.3% F2 offspring. Genotype distribution shows a clear shift to heterozygotes (WT/MUT) within all 4 breed states.

vWF serum concentration
In addition to the genetic status of vWDI, von Willebrand factor serum levels were determined during health
monitoring and results were forwarded by ProKromfohrländer e.V. or by dog owners or breeders to our laboratory. vWF serum levels were available from 64 dogs out of 87. The vWDI concentration in wild-type dogs (WT/WT) ranged from 28 to 137%. For heterozygous dogs (WT/MUT) the range was between 3 and 77%. For dogs homozygous (MUT/MUT) for the vWDI mutation the measured concentration was between 1 and 23%. The median vWF value for wild-type dogs was 94.0%, 38.5% for heterozygotes (WT/MUT) and 10.5% for homozygotes (MUT/MUT), respectively (Fig. 5). Age of first signs of bleeding symptoms was between 4 months and...
12 years with a median age of 3 years. Males showed first signs of symptoms between 1 year and 12 years with a median age of 3.3 years. In females first signs were noticed with an age of 4 months during second dentation and 8 years. The median age of female dogs was slightly lower with a value of 2.5 years compared to males with 3.3 years.

**Discussion**

The Kromfohrländer breed was established in the years after World War II based on two single founders dogs, most likely a Griffon Vendéen and a Fox Terrier. Due to the limited number of founders it is supposed that there is a high level of inbreeding within the Kromfohrländer population. A correlation between high inbreeding levels as well as a decreased genetic diversity with inherited and autoimmune disorders is widely discussed in the scientific community. Diseases such as autoimmune hemolytic anemia or polyarthritis are reported in the Kromfohrländer breed. In addition to autoimmune diseases different types of inherited disorders with

---

**Fig. 4** Distribution of von Willebrand type I symptoms in correlation with the corresponding genotype. Percentages of dogs with (symptomatic) or without symptoms (asymptomatic) were determined for each genotype group. 23.2% of heterozygotes (WT/MUT) showed bleeding symptoms compared to 45.5% of homozygous dogs (MUT/MUT). No symptoms were reported for wild-type (WT/WT) dogs without the mutation. Based on these results, hereditary of vWD-I in Kromfohrländer seems to follow an autosomal dominant inheritance with an incomplete penetrance.

**Fig. 5** Correlation of plasma von Willebrand factor with the corresponding genotype in the Kromfohrländer breed. Von Willebrand factor and the three different genotypes (wild-type (WT/WT), heterozygous (WT/MUT), homozygous (MUT/MUT)) are shown for 64 Kromfohrländer dogs. Median is indicated in green and for wild-type 94.0%, for heterozygous 38.5% and for homozygous 10.5%. Significance between plasma vWF and the different genotypes was determined by a Kruskal-Wallis test ($H = 29.5388; p$-value < 0.00001; df = 2). The result is significant at $p < 0.05$.
known causative mutations like hereditary footpad hyperkeratosis [17] or hyperuricosuria [18] have been described in the Kromfohrländer breed. Genetic screenings [16] for known inherited disorders performed for health monitoring by ProKromfohrländer e. V. revealed a very high allele frequency for the vWDI mutation which was first described in Doberman Pinscher [3, 15] and recently reported in several other dog breeds [16].

In most breeds, von Willebrand disease type I is described as an autosomal recessive bleeding disorder. In the Kromfohrländer, vWDI seems to show an autosomal dominant mode of inheritance. Patients with a type 1 disease typically show reduced levels of von Willebrand factor plasma concentration. In the present study, 87 dogs were genotyped for the known vWDI mutation. 65.5% of all study dogs were heterozygous for the vWDI mutation. From 64 participants genetic data were compared with the vWF levels obtained from blood diagnostics. Within the study population heterozygotes had a median vWF serum concentrations of 38.5%. Dogs homozygous for the vWDI mutation showed a median serum concentration of 10.5% vWF. Therefore they carry a high risk for developing symptoms of a blood coagulation disorder due to the reduced factor concentrations. In general, dogs with vWF concentrations lower than 50% are classified as “at risk” and may have bleeding episodes. Oral mucosa with gingival bleeding, epistaxis and hematuria are known clinical signs associated with vWDI as a result of the decrease in platelet function. Injuries, trauma or surgery can lead to prolonged bleeding. It is also known that not all animals having a decreased vWF level exhibit an increased tendency to bleed. Based on genotyping data and vWF serum concentrations, a direct association between the occurrence of the mutation and a reduction in serum factor concentration can be postulated. While those dogs tested as vWF wild-type have a median vWF of 94.0%, this level decreases significantly depending on whether the dog is heterozygous or homozygous for the mutation. It is obvious that such a reduction has a negative effect on blood clotting.

vWF serum levels varied significantly within each group. Dogs genetically tested as heterozygous showed vWF levels ranging from 3% up to 77%. Comparable observations were also made in dogs homozygous for the vWDI mutations ranging from 1% up to 23%. Those dogs without any mutation showed levels between 28 and 137%. Alterations in the plasma vWF level can be due to different causes. It is well known that ageing or repeated freezing and thawing during prolonged transport to the diagnostic laboratory may affect von Willebrand levels in blood samples causing decreased factor levels and subsequently a false interpretation of the results [20]. Furthermore vWF can be influenced by inflammatory conditions, hormones, medication, pregnancy, heat or lactation. In addition the plasma concentration of individual dogs varies daily and weekly and this fact may be of clinical relevance. We can’t exclude that such factors had an influence on vWF levels, leading to the variations within the three different genotype groups. Nonetheless, a genotype-dependent reduction in serum factor levels of heterozygous and homozygous dogs could be clearly shown.

The genetic status of a dog with regards to vWDI may be predicted based on the vWF plasma concentration. Dogs being heterozygous for the vWDI mutation are usually having less than half of the normal vWF plasma concentration while homozygous dogs are presented with little or no vWF protein. Von Willebrand factor concentrations between 50 and 70% do not allow an accurate prediction of the genetic status. Values in this range can be the result of a homozygote wild-type but also of a heterozygous dog of the vWDI mutation as we have also shown in this study. A similar overlap is also found in lower ranges of vWF concentrations when discriminating between heterozygotes and homozygotes. In order to prevent misinterpretation of vWF plasma concentrations, genetic testing should be carried out. Based on the genotyping results mating of dogs heterozygous or homozygous for vWDI can be avoided.

An example of a heterozygous dog with a vWF plasma concentration of 72% is shown in Fig. 6. This purebred male Kromfohrländer showed massive bruising after neutering and excision of crystals due to an inherited form of cystinuria. According to owner completed questionnaires excessive bleeding during and after surgeries or giving birth was also observed in other Kromfohrländer. Typical symptoms of bleeding were not only observed in dogs homozygous (MUT/MUT) for the vWDI mutation but also in heterozygotes (WT/MUT).

![Fig. 6 Kromfohrländer with excessive hematomas. This picture shows a male Kromfohrländer three days after neutering and surgical excision of cystine crystals and calculi due to cystinuria with massive hematomas. The dog is heterozygous (WT/MUT) for the von Willebrand type 1 mutation. The vWF serum level was determined with a value of 72%](image-url)
This is supported by the fact that in 23.2% of all heterozygotes symptoms were reported compared to 45.5% of all homozygotes while all wild-type tested dogs were asymptomatic. Based on these results, heredity of von Willebrand disease type I in the Kromfohrländer breed seems to follow an autosomal dominant inheritance with incomplete penetrance. The risk for developing symptoms increases with the number of mutated alleles and an odds ratio (OR) of a homozygous dog is 2.76 compared to a heterozygous dog. The existence of a possible second mutation linked to and acting in concert with the known causative vWDI mutation can not be excluded at the moment and might be one reason for an incomplete penetrance. Furthermore, the blood clotting cascade involves 13 different factors. Each one of these factors could have variation that influences coagulation. Thus, it is not surprising with such a complex process that variable expressivity and incomplete penetrance is present. It can be challenging to get the dog owners and breeders to understand these genetic complexities.

Due to the very high number of heterozygous dogs in the population long term breeding strategies should be realized to minimize the frequency of the vWDI allele in the breeding stock and to avoid a further distribution in the following generations of Kromfohrländer. It is important to note that such breeding strategies should not lead to a further reduction of genetic diversity and an additional increase in the inbreeding level. Based on the fact that the risk of developing bleeding symptoms is higher in homozygous (MUT/MUT) dogs than in heterozygotes (WT/MUT) we strongly recommend mandatory genetic testing of vWDI. If the vWDI genotype of stud dogs was determined, mating can be planned in a way to avoid homozygous offspring from breeding. The high allele frequency of 48% and the limited number of stud dogs within the Kromfohrländer population will need a stepwise reduction of the frequency over generations.

**Conclusion**

Von Willebrand type I mutation has been reported in a variety of breeds. Based on our results with an allele frequency of 48%, the Kromfohrländer breed is now one of them.

A comparison of the genotyping data with von Willebrand factor serum concentrations confirms a causal relationship between the occurrence of this mutation and a reduction of the serum factor level. Depending on the genotype (wild-type, heterozygous or homozygous), plasma vWF concentrations vary, leading to an increasing risk of developing bleeding symptoms with decreasing serum factor concentrations. In the case of vWD type I in the Kromfohrländer breed, it can be assumed that inheritance follows an autosomal dominant manner with incomplete penetrance, since both heterozygous as well as homozygous dogs developed classical symptoms of this coagulation disorder. To avoid further distribution of the mutant allele within the population it would be of importance to perform genetic testing of vWDI and realize a long term breeding program for reducing the allele frequency.

**Abbreviations**

MUT: Mutated; vWDI: Von Willebrand disease type I; vWF: Von Willebrand factor; WT: Wild-type

**Acknowledgements**

The authors thank the ProKromfohrländer e. V. Germany especially Britta Schmidt and Dorothee Klein for supporting us with health information and managing the delivery of owner questionnaires. Additionally we would like to thank all dog owners for the willingness to support this study.

**Funding**

There was no funding for the research and analysis reported in this paper.

**Availability of data and materials**

All data and general results generated during this study are included in this published article. Detailed data are the property of ProKromfohrländer e. V. Germany and the dog owners respectively and for that reason not available to the public. However, upon reasonable request and with the permission of the individual dog owner the data are available from the authors.

**Authors’ contributions**

AMG, JHS and WJW wrote the manuscript. JMS and AMG performed data analysis. AMG helped to create the questionnaire and collected survey data. JHS performed vWDI genotyping. All authors read and approved the final manuscript.

**Ethics approval and consent to participate**

Samples and information about the health status of participating dogs were collected with the informed consent of the owners. Pictures of Kromfohrländer dogs were kindly provided by courtesy of the dog owner.

**Consent for publication**

Not applicable.

**Competing interests**

AMG is the owner and JHS and JMS are employees of FERAGEN GmbH providing genetic testing for inherited disorders to breeders, owners and veterinarians. WJW is the owner of Specialty Pharma Service Austria e.U., working as a consultant in the field of haematology and coagulation for different pharmaceutical companies.

**Publisher’s Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Author details**

1FERAGEN GmbH, Strubergasse 26, 5020 Salzburg, Austria. 2Speciality Pharma Service Austria e.U, Altenmarkt/Triesting, Austria.

**Received** 27 February 2019 **Accepted** 5 May 2019 **Published online** 16 May 2019

**References**

1. Johnson GS, Turrentine MA, Kraus KH. Canine von Willebrand’s disease. A heterogeneous group of bleeding disorders. Vet Clin North Am Small Anim Pract. 1988;18(1):195–229.
2. Rodeghiero F, Castaman G, Dini E. Epidemiological investigation of the prevalence of von Willebrand’s disease. Blood. 1987;69(2):454–9.
3. Boudreaux MK. Inherited platelet disorders. J Vet Emerg Crit Care (San Antonio). 2012;22(1):30–41.
4. Brooks M, Raymond S, Catalfamo J. Severe, recessive von Willebrand’s disease in German wirehaired pointers. J Am Vet Med Assoc. 1996;209(5):926–9.

5. Kramer JW, Venta PJ, Klein SR, Cao Y, Schall WD, Yuzbasiyan-Gurkan V. A von Willebrand’s factor genomic nucleotide variant and polymerase chain reaction diagnostic test associated with inheritable type-2 von Willebrand’s disease in a line of German shorthaired pointer dogs. Vet Pathol. 2004;41(3):221–8.

6. Vos-Loohuis M, van Oost BA, Dangel C, Langbein-Detsch I, Leegwater PA. A novel VWF variant associated with type 2 von Willebrand disease in German wirehaired pointers and German shorthaired pointers. Anim Genet. 2017;48(4):493–6.

7. Brooks MB, Dodds JW, Raymond SL. Epidemiologic features of von Willebrand’s disease in Doberman pinschers, Scottish terriers, and Shetland sheepdogs. 260 cases (1984–1988). J Am Vet Med Assoc. 1992;200(8):1123–7.

8. Venta PJ, Li J, Yuzbasiyan-Gurkan V, Brewer GJ, Schall WD. Mutation causing von Willebrand’s disease in Scottish terriers. J Vet Intern Med. 2000;14(1):10–9.

9. Raymond SL, Jones DW, Brooks MB, Dodds WJ. Clinical and laboratory features of a severe form of von Willebrand disease in Shetland sheepdogs. J Am Vet Med Assoc. 1990;197(10):1342–6.

10. Slappendel RJ, Beijer EC, van Leeuwen M. Type III von Willebrand’s disease in Dutch kooiker dogs. Vet Q. 1998;20(3):93–7.

11. van Oost BA, Versteeg SA, Slappendel RJ. DNA testing for type III von Willebrand disease in Dutch Kooiker dogs. J Vet Intern Med. 2004;18(3):282–8.

12. Johnson GS, Lees GE, Benson RE, Rosborough TK, Dodds WJ. A bleeding disease (von Willebrand’s disease) in a Chesapeake Bay retriever. J Am Vet Med Assoc. 1981;178(11):1261–3.

13. Rieger M, Schwarz HP, Turecek PL, Donner F, van Mourik JA, Mannhalter C. Identification of mutations in the canine von Willebrand factor gene associated with type III von Willebrand disease. Thromb Haemost. 1998;80(2):332–7. https://doi.org/10.1055/s-0037-1615197.

14. Von Willebrand disease type I gene mutation. Available at: https://omia.org/OMIA001057/9615/.

15. Gentilini F, Turba ME. Two novel real-time PCR methods for genotyping the von Willebrand disease type I mutation in Doberman pincher dogs. Vet J. 2013;197(2):457–60.

16. Donner J, Kaukonen M, Anderson H, Moller F, Kyostila K, Sankari S, et al. Genetic panel screening of nearly 100 mutations reveals new insights into the breed distribution of risk variants for canine hereditary disorders. PLoS One. 2016;11(8):e0161005.

17. Droegemueller M, Jagannathan V, Becker D, Droegemueller C, Schelling C, Plaisais J, et al. A mutation in the FAM83G gene in dogs with hereditary footpad hyperkeratosis (HFH). PLoS Genet. 2014;10(5):e1004370.

18. Bannasch D, Saffa N, Young A, Karmi N, Schaible RS, Ling GV. Mutations in the SLC2A9 gene cause hyperuricosuria and hyperuricemia in the dog. PLoS Genet. 2008;4(11):e1000246.

19. Shaffer LG, Sundin K, Geretschlaeger A, Segert J, Swineburne JE, Royal R, et al. Standards and guidelines for canine clinical genetic testing laboratories. Hum Genet. 2018; https://doi.org/10.1007/s00439-018-1954-4.

20. Moser J, Meyers KM, Meinkoth JH, Brassard JA. Temporal variation and factors affecting measurement of canine von Willebrand factor. Am J Vet Res. 1996;57(9):1288–93.